380 related articles for article (PubMed ID: 19041122)
1. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma.
Zini L; Capitanio U; Perrotte P; Jeldres C; Shariat SF; Arjane P; Widmer H; Montorsi F; Patard JJ; Karakiewicz PI
Urology; 2009 Feb; 73(2):342-6. PubMed ID: 19041122
[TBL] [Abstract][Full Text] [Related]
2. Nephrectomy improves the survival of patients with locally advanced renal cell carcinoma.
Zini L; Perrotte P; Jeldres C; Capitanio U; Pharand D; Arjane P; Lapointe S; Montorsi F; Patard JJ; Karakiewicz PI
BJU Int; 2008 Dec; 102(11):1610-4. PubMed ID: 18710442
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study.
Capitanio U; Zini L; Perrotte P; Shariat SF; Jeldres C; Arjane P; Pharand D; Widmer H; Péloquin F; Montorsi F; Patard JJ; Karakiewicz PI
Urology; 2008 Nov; 72(5):1090-5. PubMed ID: 18799207
[TBL] [Abstract][Full Text] [Related]
4. A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States.
Jeldres C; Baillargeon-Gagne S; Liberman D; Isbarn H; Capitanio U; Shariat SF; Sun M; Lughezzani G; Perrotte P; Montorsi F; Graefen M; Karakiewicz PI
Urology; 2009 Oct; 74(4):837-41. PubMed ID: 19616828
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma.
Hutterer GC; Patard JJ; Colombel M; Belldegrun AS; Pfister C; Guille F; Artibani W; Montorsi F; Pantuck AJ; Karakiewicz PI
Cancer; 2007 Dec; 110(11):2428-33. PubMed ID: 17941033
[TBL] [Abstract][Full Text] [Related]
6. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
8. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed.
Pierorazio PM; McKiernan JM; McCann TR; Mohile S; Petrylak D; Benson MC
BJU Int; 2007 Oct; 100(4):755-9. PubMed ID: 17822456
[TBL] [Abstract][Full Text] [Related]
9. Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma).
Capitanio U; Perrotte P; Zini L; Jeldres C; Shariat SF; Isbarn H; Arjane P; Peloquin F; Pharand D; Montorsi F; Karakiewicz PI
BJU Int; 2009 Sep; 104(6):795-9. PubMed ID: 19389018
[TBL] [Abstract][Full Text] [Related]
10. A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses.
Zini L; Perrotte P; Jeldres C; Capitanio U; Duclos A; Jolivet-Tremblay M; Arjane P; Péloquin F; Pharand D; Villers A; Montorsi F; Patard JJ; Karakiewicz PI
BJU Int; 2009 Apr; 103(7):899-904; discussion 904. PubMed ID: 19154499
[TBL] [Abstract][Full Text] [Related]
11. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study.
Abdollah F; Sun M; Thuret R; Schmitges J; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
Ann Surg Oncol; 2011 Oct; 18(10):2988-96. PubMed ID: 21499808
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective.
Lughezzani G; Capitanio U; Jeldres C; Isbarn H; Shariat SF; Arjane P; Widmer H; Perrotte P; Montorsi F; Karakiewicz PI
Cancer; 2009 Dec; 115(24):5680-7. PubMed ID: 19824083
[TBL] [Abstract][Full Text] [Related]
13. Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment.
Crépel M; Jeldres C; Perrotte P; Capitanio U; Isbarn H; Shariat SF; Liberman D; Sun M; Lughezzani G; Arjane P; Widmer H; Graefen M; Montorsi F; Patard JJ; Karakiewicz PI
Urology; 2010 Feb; 75(2):271-5. PubMed ID: 19962740
[TBL] [Abstract][Full Text] [Related]
14. Sociodemographic factors associated with nephrectomy in patients with metastatic renal cell carcinoma.
Hellenthal NJ; Chamie K; Ramirez ML; deVere White RW
J Urol; 2009 Mar; 181(3):1013-8; discussion 1018-9. PubMed ID: 19150554
[TBL] [Abstract][Full Text] [Related]
15. External validation of an international multicenter study to predict survival in Korean patients with pT2N0M0 renal cell carcinoma.
Ku JH; Moon KC; Kwak C; Kim HH
Urology; 2009 Aug; 74(2):359-63. PubMed ID: 19501879
[TBL] [Abstract][Full Text] [Related]
16. A non-cancer-related survival benefit is associated with partial nephrectomy.
Sun M; Trinh QD; Bianchi M; Hansen J; Hanna N; Abdollah F; Shariat SF; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI
Eur Urol; 2012 Apr; 61(4):725-31. PubMed ID: 22172373
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
[TBL] [Abstract][Full Text] [Related]
18. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma.
Crépel M; Jeldres C; Sun M; Lughezzani G; Isbarn H; Alasker A; Capitanio U; Shariat SF; Arjane P; Widmer H; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
Urology; 2010 Oct; 76(4):883-8. PubMed ID: 20932408
[TBL] [Abstract][Full Text] [Related]
19. Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates?
Denzinger S; Otto W; Burger M; Hammerschmied C; Junker K; Hartmann A; Wieland WF; Walter B
World J Surg Oncol; 2007 Feb; 5():16. PubMed ID: 17280613
[TBL] [Abstract][Full Text] [Related]
20. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
